Ecthyma Gangrenosum in Wound Care: Urgent Assessment

Ecthyma Gangrenosum: What Wound Care Clinicians Must Recognize

Ecthyma gangrenosum (EG) is a cutaneous manifestation of systemic infection, most commonly associated with Pseudomonas aeruginosa bacteremia. For wound care clinicians, recognizing ecthyma gangrenosum is an urgent assessment priority because the skin lesions signal an underlying bloodstream infection that requires immediate medical intervention. This is not a wound to debride and dress. This is a wound that demands same-day medical referral and often hospitalization.

EG occurs predominantly in immunocompromised patients — those with neutropenia, hematologic malignancies, HIV/AIDS, solid organ transplants, or prolonged corticosteroid use. However, rare cases occur in immunocompetent individuals, particularly neonates and patients with diabetes. Wound care clinicians encountering an unfamiliar necrotic lesion in any immunocompromised patient should include EG in their differential.

Clinical Recognition of Ecthyma Gangrenosum

EG lesions follow a characteristic progression that, once known, is recognizable at presentation.

Lesion Evolution

Initial phase: Painless, erythematous macule or papule — often overlooked or attributed to a minor skin irritation
Vesicular or bullous phase: The macule develops a central vesicle or hemorrhagic bulla within 12 to 24 hours
Necrotic phase: The central vesicle ruptures, leaving a round or oval ulcer with a necrotic black eschar surrounded by an erythematous halo
Established lesion: A well-demarcated ulcer with a gray-black necrotic center and an erythematous, indurated border. The surrounding skin may show livedo-like discoloration.

Distinguishing Features

Location: EG most commonly appears in the anogenital and axillary regions, but can occur anywhere. Gluteal involvement is classic.
Number: Lesions may be solitary or multiple. Multiple lesions increase the likelihood of bacteremia.
Rapid evolution: The hallmark is the speed of progression from macule to necrotic ulcer within 24 to 48 hours.
Disproportionate necrosis: The degree of tissue necrosis appears excessive relative to the lesion size, suggesting a vascular mechanism rather than direct tissue invasion.

The Vascular Mechanism

EG lesions result from bacterial invasion of blood vessel walls (perivascular bacterial invasion) causing vasculitis and subsequent thrombosis. The necrosis is ischemic — the bacteria destroy the vessel, blood flow ceases, and the tissue supplied by that vessel dies. This explains the sharp borders and characteristic eschar.

Pseudomonas Association and Other Causes

While Pseudomonas aeruginosa is the organism most classically associated with EG, other pathogens can produce identical lesions.

Pseudomonas aeruginosa accounts for the majority of EG cases. In the context of neutropenic fever or known Pseudomonas bacteremia, new necrotic skin lesions should be assumed to be EG until proven otherwise.

Other organisms that can cause EG-like lesions:

Aeromonas hydrophila
Stenotrophomonas maltophilia
Escherichia coli
Klebsiella pneumoniae
Candida species (particularly in neonates)
Aspergillus species
Fusarium species

The specific organism matters for antibiotic selection but does not change the wound care clinician's immediate response: urgent medical referral.

Urgent Medical Referral Protocol

When EG is suspected, the wound care clinician's responsibilities are:

Do not debride the lesion. The necrotic eschar in EG is not amenable to wound care debridement. The underlying cause is vascular, and debridement does not address it.
Obtain wound culture if not yet collected — swab the base of the lesion after removing the eschar edge. However, blood cultures obtained by the receiving medical team are more diagnostic than wound cultures.
Refer to the patient's primary care provider, oncologist, or infectious disease specialist immediately — same-day contact. If the patient is actively febrile or hemodynamically unstable, this is an emergency department presentation.
Document the lesion — photograph, measure, describe the morphology (eschar, border, surrounding skin changes), and note the timeline of development
Review the patient's medication and immune status — current immunosuppressive medications, recent chemotherapy, known neutropenia, HIV status

For broader guidance on wound assessment in immunocompromised patients, see Wound Care for Immunocompromised Patients.

The Wound Care Clinician's Role After Diagnosis

Once EG is diagnosed and the patient is receiving systemic antimicrobial therapy (typically anti-pseudomonal antibiotics such as piperacillin-tazobactam, cefepime, or meropenem, often combined with an aminoglycoside), wound care clinicians may be asked to manage the resulting wounds during recovery.

Post-treatment wound management:

Eschar separation: As the infection is controlled and blood flow is restored to viable tissue, the necrotic eschar will demarcate. Autolytic debridement with moisture-retentive dressings is preferred over sharp debridement in immunocompromised patients.
Wound bed preparation: Once the eschar separates, the wound base is managed with standard moist wound healing principles — granulation tissue promotion, moisture balance, and infection surveillance.
Dressing selection: Non-adherent silicone contact layers with absorbent foam secondary dressings. Antimicrobial dressings (silver-containing) may be appropriate given the patient's immunocompromised state.
Healing timeline: EG wounds typically heal once the systemic infection is controlled and the patient's immune function recovers. Persistent non-healing should prompt reassessment of immune status and possible re-culture.

For a structured approach to assessing wound infection, see Wound Care Infection Assessment.

Documentation Requirements

EG cases require thorough documentation because they involve coordination across multiple providers and represent a significant clinical event.

Initial presentation: Date and time of first observation, lesion description, patient immune status, current medications
Referral communication: Name and specialty of the provider contacted, time of contact, clinical information communicated
Serial wound assessments: Measurements, photographs, tissue type, and wound bed changes as the lesion responds (or fails to respond) to systemic treatment
Coordination notes: Communication with oncology, infectious disease, or primary care regarding wound trajectory

Key Takeaways

Ecthyma gangrenosum is a cutaneous sign of systemic infection, most commonly Pseudomonas bacteremia, and requires urgent same-day medical referral — not wound care debridement.
The characteristic lesion is a rapidly evolving necrotic ulcer with black eschar and erythematous border, progressing from macule to necrosis within 24 to 48 hours.
EG occurs predominantly in immunocompromised patients (neutropenia, malignancy, transplant, HIV) but can occur in immunocompetent neonates and diabetics.
The wound care clinician's primary role is recognition and referral; post-treatment wound management begins only after systemic antimicrobial therapy is established.
Document the lesion, the timeline, the referral communication, and serial wound assessments to support the multidisciplinary treatment record.